Tonix Pharmaceuticals Holding Corp.
TNXP Healthcare Biotechnology
Tonix Pharmaceuticals Holding Corp.’s revenue for fiscal 2025 (year ended December 2025) was $13.1 million, up 29.8% from fiscal 2024. In the quarter to June 2026, revenue grew 577.9%, EPS grew 36.8% and free cash flow fell 178.8%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow TNXP
Tonix Pharmaceuticals Holding Corp. (TNXP) EV/Sales
As of 16 October 2026, Tonix Pharmaceuticals Holding Corp. (TNXP) trades at a EV/Sales of −2.3×. Over the past ten years it has ranged from −8.5× (March 2025) to 33.9× (August 2025); the current reading is higher than 5% of that period. That is below the Biotechnology industry median of 9.2× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | −5.1× | — |
| FY2024 | −6.6× | — |
| FY2023 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 1.5× | 150.29% |
| Mar 2026 | 0.6× | — |
| Dec 2025 | −5.1× | — |
| Sep 2025 | 3.2× | (78.39%) |
| 8 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| LENZ LENZ Therapeutics, Inc. compare | −5.4× |
| SEER Seer, Inc. compare | −2.9× |
| TNXP Tonix Pharmaceuticals Holding Corp. | −2.3× |
| FHTX Foghorn Therapeutics Inc. compare | −0.5× |
| ENGN enGene Therapeutics Inc compare | n/m |
| CYTT Cyteir Therapeutics, Inc. compare | n/m |
| VTVT vTv Therapeutics Inc. compare | 6.5× |
| GNLX Genelux Corporation compare | 8.8× |
| INO Inovio Pharmaceuticals, Inc. compare | 157× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)